My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 101

    1.

    Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes.

    Rosenstock J, Cefalu WT, Hollander PA, Belanger A, Eliaschewitz FG, Gross JL, Klioze SS, St Aubin LB, Foyt H, Ogawa M, Duggan WT.

    Diabetes Care. 2008 Sep;31(9):1723-8. Epub 2008 Jun 5.PMID: 18535196 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes.

    Skyler JS, Jovanovic L, Klioze S, Reis J, Duggan W; Inhaled Human Insulin Type 1 Diabetes Study Group.

    Diabetes Care. 2007 Mar;30(3):579-85.PMID: 17327324 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Randomized study to characterize glycemic control and short-term pulmonary function in patients with type 1 diabetes receiving inhaled human insulin (exubera).

    Norwood P, Dumas R, Cefalu W, Yale JF, England R, Riese R, Teeter J.

    J Clin Endocrinol Metab. 2007 Jun;92(6):2211-4. Epub 2006 Sep 26.PMID: 17003088 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial.

    Quattrin T, Bélanger A, Bohannon NJ, Schwartz SL; Exubera Phase III Study Group.

    Diabetes Care. 2004 Nov;27(11):2622-7.PMID: 15504996 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Safety and efficacy of inhaled human insulin (Exubera) during discontinuation and readministration of therapy in adults with type 1 diabetes: A 3-year randomized controlled trial.

    Skyler JS, Hollander PA, Jovanovic L, Klioze S, Krasner A, Riese RJ, Reis J, Schwartz P, Duggan W; Inhaled Human Insulin Type 1 Diabetes Study Group.

    Diabetes Res Clin Pract. 2008 Nov;82(2):238-46. Epub 2008 Sep 27.PMID: 18824271 [PubMed - indexed for MEDLINE]Related articles

    6.

    Assessment of long-term immunological and pulmonary safety of inhaled human insulin with up to 24 months of continuous therapy.

    Cefalu WT, Bohannon NJ, Fineberg SE, Teeter JG, Schwartz PF, Reis JM, Krasner AS.

    Curr Med Res Opin. 2008 Sep 30. [Epub ahead of print]PMID: 18828959 [PubMed - as supplied by publisher]Related articles

    7.

    Efficacy and safety of inhaled human insulin (Exubera) compared to subcutaneous insulin in children ages 6 to 11 years with type 1 diabetes mellitus: results of a 3-month, randomized, parallel trial.

    White NH, Quattrin T, St Aubin LB, Duggan WT, England RD, Fryburg JS.

    J Pediatr Endocrinol Metab. 2008 Jun;21(6):555-68.PMID: 18717242 [PubMed - indexed for MEDLINE]Related articles

    8.

    Long-term tolerability of inhaled human insulin (Exubera) in patients with poorly controlled type 2 diabetes.

    Barnett AH, Lange P, Dreyer M, Serdarevic-Pehar M; Exubera Phase 3 Study Group.

    Int J Clin Pract. 2007 Oct;61(10):1614-25. Erratum in: Int J Clin Pract. 2008 Jan;62(1):171. PMID: 17877648 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus.

    Ceglia L, Lau J, Pittas AG.

    Ann Intern Med. 2006 Nov 7;145(9):665-75.PMID: 17088580 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Inhaled human insulin (Exubera): a review of its use in adult patients with diabetes mellitus.

    Dunn C, Curran MP.

    Drugs. 2006;66(7):1013-32. Review.PMID: 16740022 [PubMed - indexed for MEDLINE]Related articles

    11.

    Safety and efficacy of inhaled insulin (AERx iDMS) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial.

    Moses RG, Bartley P, Lunt H, O'Brien RC, Donnelly T, Gall MA, Vesterager A, Wollmer P, Roberts A.

    Diabet Med. 2009 Mar;26(3):260-7.PMID: 19317821 [PubMed - indexed for MEDLINE]Related articles

    12.

    An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea.

    Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M.

    Diabetes Care. 2006 Jun;29(6):1282-7.PMID: 16732009 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial.

    Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, Gerstein HC; Inhaled Insulin Phase III Type 1 Diabetes Study Group.

    Diabetes Care. 2005 Jul;28(7):1630-5.PMID: 15983312 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Safety and efficacy of inhaled human insulin (exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial.

    Rosenstock J, Cefalu WT, Hollander PA, Klioze SS, Reis J, Duggan WT.

    Diabetes Technol Ther. 2009 Nov;11(11):697-705.PMID: 19905885 [PubMed - in process]Related articles

    15.

    Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes.

    Hompesch M, Kollmeier A, Rave K, Heinemann L, Mitnick M, Davies S, Strack T.

    Diabetes Technol Ther. 2009 May;11(5):307-13.PMID: 19537357 [PubMed - indexed for MEDLINE]Related articles

    16.

    Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial.

    Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK, Hendler R, Lan SP, Cefalu WT.

    Ann Intern Med. 2005 Oct 18;143(8):549-58.PMID: 16230721 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial.

    Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson JL, Levin SR.

    Diabetes Care. 2004 Oct;27(10):2356-62.PMID: 15451900 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes.

    Hermansen K, Rönnemaa T, Petersen AH, Bellaire S, Adamson U.

    Diabetes Care. 2004 Jan;27(1):162-7.PMID: 14693983 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.

    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.

    Clin Ther. 2008 Nov;30(11):1976-87.PMID: 19108786 [PubMed - indexed for MEDLINE]Related articles

    20.

    Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.

    Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.

    Ann Intern Med. 2008 Oct 21;149(8):531-9.PMID: 18936501 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is temporarily unavailable.

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    » See more...